KENNETH BATE - 15 Aug 2025 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Director
Signature
/s/ Mardi Dier, as Attorney-in-Fact
Issuer symbol
MDGL
Transactions as of
15 Aug 2025
Net transactions value
-$3,487,409
Form type
4
Filing time
15 Aug 2025, 18:04:57 UTC
Previous filing
24 Jun 2025
Next filing
07 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BATE KENNETH Director C/O MADRIGAL PHARMACEUTICALS, INC., 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN /s/ Mardi Dier, as Attorney-in-Fact 15 Aug 2025 0001210238

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Options Exercise $164,600 +10,000 +381% $16.46 12,627 15 Aug 2025 Direct
transaction MDGL Common Stock Sale $842,014 -2,317 -18% $363.41 10,310 15 Aug 2025 Direct F1
transaction MDGL Common Stock Sale $916,428 -2,516 -24% $364.24 7,794 15 Aug 2025 Direct F2
transaction MDGL Common Stock Sale $937,793 -2,567 -33% $365.33 5,227 15 Aug 2025 Direct F3
transaction MDGL Common Stock Sale $219,683 -600 -11% $366.14 4,627 15 Aug 2025 Direct F4
transaction MDGL Common Stock Sale $405,865 -1,104 -24% $367.63 3,523 15 Aug 2025 Direct F5
transaction MDGL Common Stock Sale $330,226 -896 -25% $368.56 2,627 15 Aug 2025 Direct F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -10,000 -100% $0.000000 0 15 Aug 2025 Common Stock 10,000 $16.46 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.87 to $363.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.88 to $364.87, inclusive.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $364.91 to $365.77, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.00 to $366.22, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $367.115 to $368.05, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $368.13 to $368.98, inclusive.
F7 The shares underlying this stock option are fully vested and exercisable.